Moleculin Biotech, Inc.

Moleculin Biotech, Inc. Annual Report Summary

Moleculin Biotech, Inc. (Nasdaq: MBRX) is a clinical-stage pharmaceutical company on a mission to develop innovative small molecule drugs. They focus on tackling difficult-to-treat cancers and viral diseases, with their lead drug candidates currently advancing through various phases of clinical trials. As a "smaller reporting company" and "non-accelerated filer," Moleculin Biotech operates with fewer reporting requirements than larger firms, reflecting its smaller market capitalization. The company's fiscal year ended on December 31, 2025. This past year saw Moleculin Biotech primarily focused on moving its drug pipeline forward and securing essential funding amidst a challenging capital market.

1. Business Overview Moleculin Biotech, Inc. (Nasdaq: MBRX) is a clinical-stage pharmaceutical company dedicated to developing innovative small molecule drugs for difficult-to-treat cancers and viral diseases. Its lead drug candidates are currently advancing through various phases of clinical trials. As a "smaller reporting company" and "non-accelerated filer," Moleculin Biotech has fewer reporting requirements than larger firms, a status that reflects its smaller market capitalization. The company's fiscal year ended on December 31, 2025. During this past year, Moleculin Biotech primarily focused on advancing its clinical pipeline and securing necessary funding, navigating a challenging capital market environment.

2. Financial Performance As a clinical-stage company, Moleculin Biotech generated no significant product revenue for the fiscal year ended December 31, 2025. The company continued to report a net loss, primarily due to substantial research and development (R&D) expenses as it advanced its drug candidates through clinical trials.

To fund these operations and ongoing clinical development, the company undertook significant capital-raising activities, which notably changed its stock structure. On December 1, 2025, Moleculin Biotech completed a reverse stock split. While this action typically increases the price per share to help meet exchange listing requirements, it does not change the company's underlying value.

Despite the reverse split, the number of common shares outstanding increased dramatically: from approximately 135,155 shares at the end of 2024 to roughly 3,199,228 shares by the end of 2025. This trend continued into early 2026, reaching 5,336,350 shares as of March 11, 2026. This substantial increase, even after a reverse split, indicates significant dilution for existing shareholders. Dilution means their ownership stake is spread across many more shares. While a common method for early-stage biotechs to raise capital, dilution can pressure the stock price.

The company's market value for shares held by non-affiliates stood at approximately $8.8 million as of the second quarter of 2025, underscoring its status as a small-cap company.

3. Risk Factors Beyond the significant dilution of shares (from 135,155 at year-end 2024 to over 5 million by early 2026) and the reverse stock split (often a sign of financial distress or a low stock price), several other critical risks could impact Moleculin Biotech's stock price:

• Clinical Trial Risk: The success of the company's drug candidates remains highly uncertain. Any negative or inconclusive clinical trial results, delays in patient enrollment, or unexpected safety issues could severely impact Moleculin Biotech's prospects.
• Regulatory Risk: Obtaining FDA or other regulatory approvals is a long, complex, and uncertain process. Failure to secure these approvals would prevent the company from commercializing its drugs.
• Funding Risk: As a pre-revenue company, Moleculin Biotech heavily relies on its ability to raise additional capital. Failure to secure future funding could force the company to delay or abandon development programs.
• Competition: The oncology and antiviral markets are fiercely competitive. New therapies from larger, better-funded companies could reduce the market potential of Moleculin's drug candidates.
• Intellectual Property: Protecting its drug candidates through patents and other intellectual property (IP) is crucial. Any challenges to its IP could undermine the company's competitive position.
• Operational Risks: As a "smaller reporting company," Moleculin Biotech may have limited resources, less diversified operations, and greater sensitivity to market changes compared to larger pharmaceutical companies.

4. Management Discussion

Major Wins and Challenges: Moleculin Biotech reported progress in its clinical development pipeline. This progress involved initiating or advancing specific clinical trials for key drug candidates like Annamycin or WP1066. Securing additional financing, despite its dilutive effect, was critical for sustaining operations. The primary challenge involved securing sufficient capital to fund its extensive R&D efforts, as evidenced by the significant share dilution.

5. Financial Health Moleculin Biotech's financial health is characterized by its reliance on external funding to support operations. The company experiences a significant cash burn rate due to ongoing R&D and administrative expenses. The substantial capital raises through equity issuance (leading to dilution) indicate a continuous need for funding to maintain operations and advance its pipeline, suggesting a limited cash runway without further financing.

6. Future Outlook Looking ahead, Moleculin Biotech's future outlook primarily depends on the successful progression of its clinical trials for lead drug candidates. Key milestones for the upcoming year include reporting data from ongoing studies, initiating new clinical trials, and seeking regulatory designations (e.g., Orphan Drug status). Continued efforts to secure additional financing will remain critical to sustain operations and fund these development activities. The company's ability to achieve these milestones and manage its cash resources will be paramount to its long-term viability.

7. Competitive Position Moleculin Biotech operates in highly competitive therapeutic areas, particularly oncology. Its competitive positioning relies on the potential differentiation of its small molecule drug candidates, such as novel mechanisms of action or efficacy in patient populations resistant to existing treatments. The company competes with larger pharmaceutical companies and other biotech firms that possess greater financial, technical, and human resources. Success hinges on demonstrating superior efficacy and safety profiles in clinical trials compared to current standards of care or other drugs in development.

When considering Moleculin Biotech, it's important to weigh the potential for groundbreaking drug development against the significant financial risks inherent in a clinical-stage biotech, especially the ongoing need for capital and the resulting shareholder dilution.